Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark
Published ·
Keep reading
Related stories
